These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension. Palmieri V; Devereux RB Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398 [TBL] [Abstract][Full Text] [Related]
26. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164 [TBL] [Abstract][Full Text] [Related]
27. Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Suzuki H; Schaefer L; Ling H; Schaefer RM; Dämmrich J; Teschner M; Heidland A Am J Nephrol; 1995; 15(2):129-36. PubMed ID: 7733149 [TBL] [Abstract][Full Text] [Related]
28. Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Sanada S; Node K; Minamino T; Takashima S; Ogai A; Asanuma H; Ogita H; Liao Y; Asakura M; Kim J; Hori M; Kitakaze M Hypertension; 2003 Apr; 41(4):963-7. PubMed ID: 12629037 [TBL] [Abstract][Full Text] [Related]
29. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Avanza AC; El Aouar LM; Mill JG Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284 [TBL] [Abstract][Full Text] [Related]
30. Numerical density of cardiomyocytes in chronic nitric oxide synthesis inhibition. Mandarim-De-Lacerda CA; Meirelles Pereira LM Pathobiology; 2000; 68(1):36-42. PubMed ID: 10859529 [TBL] [Abstract][Full Text] [Related]
32. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753 [TBL] [Abstract][Full Text] [Related]
33. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I. Donohue TJ; Dworkin LD; Ma J; Lango MN; Catanese VM J Investig Med; 1997 Dec; 45(9):584-91. PubMed ID: 9444886 [TBL] [Abstract][Full Text] [Related]
34. [The stereology of the myocardium in rats hypertensive due to the use of an inhibitor of nitric oxide synthesis]. Pereira LM; Mandarim-de-Lacerda CA Rev Port Cardiol; 1997 Oct; 16(10):753-9, 743. PubMed ID: 9479938 [TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975 [TBL] [Abstract][Full Text] [Related]
36. Stereology of the myocardium in hypertensive rats. Differences in relation to the time of inhibition of nitric oxide synthesis. Pereira LM; Vianna GM; Mandarim-de-Lacerda CA Virchows Arch; 1998 Oct; 433(4):369-73. PubMed ID: 9808439 [TBL] [Abstract][Full Text] [Related]
37. Protection against L-NAME-induced reduction in cardiac output persists even after cessation of angiotensin-converting enzyme inhibitor treatment. Biwer LA; Broderick TL; Xu H; Carroll C; Hale TM Acta Physiol (Oxf); 2013 Jan; 207(1):156-65. PubMed ID: 22834875 [TBL] [Abstract][Full Text] [Related]
38. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Dyadyk AI; Bagriy AE; Lebed IA; Yarovaya NF; Schukina EV; Taradin GG Nephrol Dial Transplant; 1997 May; 12(5):945-51. PubMed ID: 9175047 [TBL] [Abstract][Full Text] [Related]
39. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. Gosse P; Roudaut R; Herrero G; Dallocchio M J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S145-50. PubMed ID: 11527119 [TBL] [Abstract][Full Text] [Related]
40. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)]. Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]